Citation for published version (APA):
Wilson, S., Partos, T., McNeill, A., & Brose, L. S. (2019). Harm perceptions of e-cigarettes and other nicotine products in a UK sample. *Addiction, 114*(5), 879-888. https://doi.org/10.1111/add.14502
Harm perceptions of e-cigarettes and other nicotine products in a UK sample

Samara Wilson¹, Timea Partos¹, Ann McNeill¹,² & Leonie S. Brose¹,²

Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK¹ and UK Centre for Tobacco and Alcohol Studies, UK²

ABSTRACT

Background and aims  E-cigarettes (EC) and nicotine replacement therapy (NRT) are less harmful than smoking, but misperceptions of relative harm are common. Aims were to (1) assess nicotine knowledge and perceptions of: harm of EC and NRT relative to smoking, addictiveness of EC relative to smoking, and change in harm to user if smoking replaced with EC; (2) define associations of these perceptions with respondent characteristics including nicotine knowledge; and (3) explore perceived main harms of EC and whether these differ by vaping status.

Design  Analyses were: (1) frequencies; (2) logistic regressions of perceptions of relative harm, addictiveness and change in harm onto demographics, smoking and vaping status and nicotine knowledge (attributing cancer or health risks of smoking to nicotine); and (3) frequencies and χ² statistics.

Setting and participants  Participants were smokers and recent ex-smokers from one wave (September 2017) of a longitudinal online survey in the United Kingdom (n = 1720).

Measurements  Demographics included gender, age, smoking status, vaping status and income. Survey questions collected data on nicotine knowledge and harm perceptions of different products; the relative harm perceptions of NRT, EC and tobacco cigarettes; and perceived main harms of EC.

Findings  Relative to smoking, 57.3% perceived EC and 63.4% NRT to be less harmful; 25.4% perceived EC to be less addictive; and 32.2% thought replacing smoking with EC reduced health harms a great deal. Participants were less likely to endorse these beliefs if they had never vaped, and participants who had inaccurate nicotine knowledge were less likely to endorse all these beliefs apart from the addictiveness of EC. The main concerns about EC were a lack of research (48.3%), regulation or quality control (37.8%) and harmfulness of chemicals (41.6%).

Conclusions  Large proportions of UK smokers and ex-smokers overestimate the relative harmfulness of e-cigarettes and nicotine replacement therapy compared with smoking; misattributing smoking harms to nicotine is associated with increased misperceptions.

Keywords  Electronic cigarettes, electronic nicotine delivery systems, harm perception, harm reduction, nicotine replacement products, smoking, vaping.

INTRODUCTION

Smoking tobacco cigarettes is one of the most dangerous behaviours, as it kills more than half of those with sustained use. There are many health harms from smoking, such as increased risk of heart attack, stroke and many cancers. Nicotine is the main addictive substance in smoking, but it is the other constituents that cause the harms [1]. Nicotine is also used in nicotine replacement therapy (NRT), which does not have the same level of health risks associated with smoking. For example, the Royal College of Physicians report [2] found no increased risk of heart attack, stroke or death from using NRT when attempting to quit smoking. The Lung Health study [3], a 5-year randomized controlled trial (RCT) with a 7.5-year follow-up, found no link between NRT and cancers, whereas there was a relationship between smoking and cancer. Electronic cigarettes (EC) can also contain nicotine and are less harmful than smoking [2,4–6]; however, there are many misperceptions in the community concerning the level of harm presented by nicotine, and the relative harm of smoking tobacco cigarettes versus NRT and EC [4,5,7,8]. It is possible that misperceptions of nicotine’s risks are underpinning harm perceptions of NRT and EC, but evidence on this potential association is lacking.

© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
It is currently unclear how harm misperceptions of different products affect their use, as findings have been mixed. Brose et al. [9] looked at harm perceptions of EC among past-year smokers, and found that perceiving EC to be less harmful predicted subsequent initiation of EC use. However, Black et al. [10] did not find a link between accurate nicotine knowledge and NRT usage.

Both internationally and among adults and youth in Great Britain, harm perceptions of nicotine and EC were not improving over time [4,11–14]. The 2014 Tobacco Products Directive (revised EU TPD) placed regulations on EC, such as restricting nicotine concentration and the size of tanks and refill bottles [4]. These regulations, which became applicable in the UK between 20 May 2016 and 20 May 2017, could potentially influence smokers into believing EC are more harmful than they are, or could reassure smokers about the safety of the EC products on the market after EU TPD implementation. This makes current harm perceptions highly relevant to investigate.

This study used a web-based national sample of past-year smokers from the general population in the UK and aimed to (1) assess nicotine knowledge and perceptions of harm of EC and NRT relative to smoking, addictiveness of EC relative to smoking and change in harm to user if smoking replaced with EC; (2) associations of these perceptions with respondent characteristics including nicotine knowledge; and (3) explore perceived main harms of EC and whether these differ by vaping status.

METHODS

Participants and design

Data from a UK longitudinal online survey were used. Members of an online panel managed by Ipsos MORI were invited by e-mail to participate in a study about smoking by Ipsos Interactive Services in return for points, which could be redeemed as shopping vouchers or used to enter prize draws. At baseline, of the 23 785 invited participants, 6165 were eligible to participate, being past-year smokers, i.e. reported that they smoked cigarettes (including hand-rolled) every day or some days, smoked tobacco of some kind (e.g. pipe or cigar) or had stopped smoking completely in the past year [15]. To ensure representativeness of the British population, quotas were imposed based on age, gender and region at recruitment. In November and December 2012, 5000 participants completed the baseline/wave 1 survey, 2182 of the original participants completed the survey in wave 2 (December 2013) and 1519 in wave 3 (December 2014). In wave 4 (May/June 2016), the sample was replenished using the same approach as for wave 1, with quotas again imposed based on age, gender and region, resulting in 3334 survey completions (n = 931 continuing from wave 1 and n = 2403 newly recruited). At wave 5 (September 2017), 1720 participants completed the survey. This current paper analyses data from wave 5.

Measures

Demographics

Demographic variables included gender (male or female) and age. Smoking status (daily, non-daily, other tobacco, recent quit, quit more than 1 year ago) was recoded into daily smoker, non-daily smoker and ex-smoker. Vaping status (daily, non-daily, only a few times, recent quit, quit more than 1 year ago, never vaped) was recoded into daily vapor, non-daily vapor, trier, ex-vaper and never vapor. Income was grouped as low (under £15 000), moderate (£15 001–30 000), high (more than £30 000) or not disclosed. The wording of the measures is provided in Supplementary table 1.

Nicotine knowledge and harm perceptions of different products

Four items from the survey assessed relative harm perceptions of NRT, EC, nicotine and tobacco cigarettes, and two items assessed nicotine knowledge. Binary recoding categories were selected in which one category was designated accurate based on the Royal College of Physician’s report on tobacco harm reduction (2016).

Items for nicotine knowledge were:

- ‘According to what you know or believe, what portion of the health risks of smoking comes from nicotine in tobacco cigarettes?’ Response options were: ‘none or very small; some but well under half the risk; around half the risk; much more than half the risk; nearly all the risk; don’t know’. This was recoded as a binary variable with two levels: none or very small risk (the correct answer) versus all other response options.
- ‘The nicotine in tobacco cigarettes is the chemical that causes most of the cancer?’ Response options were ‘true’ or ‘false’. False was the correct answer.

Items for the relative harm perceptions of NRT, EC and tobacco cigarettes were:

- ‘Do you think electronic cigarettes/vaping devices are more harmful than smoking tobacco cigarettes, less harmful, or are they equally harmful to health?’ Response options were: ‘more harmful than tobacco cigarettes; equally harmful; less harmful than tobacco cigarettes; don’t know’. This was dichotomized into ‘EC are less harmful than tobacco cigarettes’ (correct answer) versus all other responses.
- ‘Do you think nicotine replacement therapies such as gums or patches are more harmful than smoking tobacco cigarettes, less harmful, or are they equally harmful?’ Response options were the same as the previous item. This was dichotomized as NRT is less harmful than tobacco cigarettes (correct answer) versus all other categories.
• ‘Do you think electronic cigarettes/vaping devices (with nicotine) are more addictive than tobacco cigarettes, less addictive, or are they equally addictive?’ Response options were: ‘more addictive than tobacco cigarettes; equally addictive; less addictive than tobacco cigarettes; don’t know’. This variable was dichotomized as less addictive versus all other responses.

• ‘Now imagine a smoker who smokes 10 tobacco cigarettes a day stops smoking tobacco cigarettes altogether and continues to use electronic cigarettes or vaping devices daily. How would that change any harm to their health from smoking and vaping?’ Response options were: ‘would reduce health harms a lot; would reduce health harms a little; would not change harm at all; would increase health harms a little; would increase health harms a lot; don’t know’. This was dichotomized as would reduce health harms a lot versus all other response options.

Perceived main harms of EC

Participants were asked: ‘What in your view are the main harms, if any, of EC/vaping devices?’, followed by 11 options with yes/no responses: ‘there are no harms; they may be addictive; they may explode or catch fire; they may cause breathing/respiratory problems; they may cause cancer; there has not been enough research done to understand all the possible harms; the chemicals in the liquid might be harmful; the nicotine; there is not enough quality control or regulation—you don’t know exactly what chemicals they may contain; they reinforce the smoking habit; they may cause heart disease’. These items represented a summary of concerns provided by participants in wave 4 to an open response item which asked about the main harms of EC/vaping devices.

Data analysis

Data were analysed using Stata version 15. The analyses involved a cross-sectional design using wave 5 data. Alpha was set at 0.05. An attrition analysis examined differences between respondents followed-up at wave 5 versus those lost to attrition using Pearson’s χ² analyses.

Aim 1: Nicotine knowledge and relative harm perceptions of EC, NRT and smoking

Frequencies to the responses to the two nicotine knowledge items and the four harm perception items were calculated.

Aim 2: Associations of relative harm perceptions with respondent characteristics including nicotine knowledge

Bivariate and multivariable logistic regressions were used to assess associations between harm perception and demographics, smoking and EC use status and nicotine knowledge.

Results from multivariable analyses are reported in the table, and where bivariate results markedly differed this is noted in text.

Aim 3: Perceived main harms of EC

Frequencies of the 11 items on the perceived main harms of EC were calculated, and a χ² analysis was conducted to compare whether these frequencies differed based on vaping status. Adjusted standardized residuals (greater than 2 and 3 standard deviations marked) were used to explore where these differences were among the vaping status categories.

RESULTS

Demographics

Our sample had a mean age of 49.4 years; other demographic, smoking and vaping characteristics are described in Table 1. Respondents followed-up at wave 5 versus those lost to attrition were significantly more likely to be older age groups (χ²(5) = 184.56, P < 0.001), more likely to have never vaped and less likely to have vaped only a few times (χ²(5) = 34.66, P < 0.001), less likely to be non-daily smokers (χ²(5) = 27.50, P < 0.001) and less likely to have a high income (χ²(5) = 17.10, P = 0.001). They did not differ on gender.

Table 1 Sample description, n = 1720.

| Characteristics (wave 5) | % (n) |
|--------------------------|-------|
| Gender                   |       |
| Female                   | 44.1 (758) |
| Male                     | 55.9 (962) |
| Age (years)              |       |
| 18–24                    | 4.9 (85) |
| 25–34                    | 14.4 (247) |
| 35–44                    | 18.2 (313) |
| 45–54                    | 24.5 (422) |
| 55–64                    | 18.3 (314) |
| 65+                      | 19.7 (339) |
| Smoking status           |       |
| Daily smoker             | 51.4 (884) |
| Non-daily smoker         | 15.9 (274) |
| Ex-smoker                | 32.7 (562) |
| Vaping status            |       |
| Never vaped              | 39.0 (670) |
| Daily vapor              | 17.6 (302) |
| Non-daily vapor          | 12.4 (214) |
| Trier                    | 17.1 (294) |
| Ex-vaper                 | 14.0 (240) |
| Income                   |       |
| Low (£15 000)            | 20.9 (359) |
| Moderate (£15 001–30 000) | 29.9 (514) |
| High (>£30 000)          | 40.1 (690) |
| Not disclosed            | 9.1 (157) |

© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Nicotine knowledge

For the portion of health risk which comes from nicotine in cigarettes, 11.2% responded none or very small, 24.5% responded some but well under half, 21.8% responded approximately half the risk, 16.3% responded much more than half the risk, 11.5% responded nearly all the risk and 14.8% responded that they did not know. In adjusted analyses, being aged 55–64 or 35–44 years (versus 65+) and being a daily vapor or vaping trier (versus never vapor) were associated with higher odds of responding that a very small proportion of the health risk in cigarettes comes from nicotine (Table 2).

When asked whether the nicotine in tobacco cigarettes is the chemical that causes most of the cancer, 39.2% responded true (the incorrect response) and 60.8% responded false (the accurate response). In adjusted analyses, being aged 45–54 years (versus 65+), a daily vapor or vaping trier (versus never vapor) were significantly associated with higher odds of endorsing that nicotine in cigarettes is not what causes most of the cancer (Table 2).

Relative harm perceptions and addictiveness perceptions of EC, NRT and smoking, and associations with respondent characteristics

For the relative harmfulness of EC and tobacco cigarettes, 3.3% responded that EC were more harmful than tobacco cigarettes, 21.8% responded equally harmful, 57.3% responded less harmful and 17.6% responded they did not know. In the multivariable analysis, being in any of the age groups between 25–54 was associated with lesser odds, and being an ex-smoker or having ever vaped were associated with greater odds for perceiving EC as less harmful than tobacco cigarettes versus all the other responses (Table 3). Bivariate analyses did not find a difference for ages 35–54.

For the relative harm of NRT and tobacco cigarettes, 1.9% responded that NRT was more harmful than tobacco cigarettes, 15.2% responded equally harmful, 63.4% responded less harmful and 19.5% responded that they did not know. In the multivariable analysis, being aged 25–34 years was associated with lower odds, whereas trying vaping or having a high income were associated with greater odds, of rating NRT as less harmful than tobacco cigarettes versus all other outcomes (Table 3).

When asked about the relative addictiveness of EC compared to tobacco cigarettes, 4.7% responded that EC are more addictive, 49.0% responded equally addictive, 25.4% responded less addictive and 20.9% responded that they did not know. Being male, or having ever rather than never vaped, were associated with higher odds of responding that EC are less addictive than tobacco cigarettes versus all other outcomes in adjusted analyses (Table 3).

For the change in harm of stopping tobacco cigarettes and using EC instead, 32.2% responded that this would reduce health harms a great deal, 33.0% responded that this would reduce health harms a little, 13.0% responded this would not change harm at all, 2.8% responded this would increase health harms a little, 1.5% responded this would increase health harms a great deal and 17.5% did not know. In adjusted analyses, being aged 25–54 was associated with lower odds, and having ever vaped compared to never vaped was associated with higher odds, of responding that it would reduce health harms a great if a smoker stopped smoking cigarettes and started using EC instead (Table 3).

Accurate nicotine knowledge was associated with greater odds of responding that: EC are less harmful than tobacco cigarettes; NRT are less harmful than tobacco cigarettes; health harms would reduce a great deal if a smoker stopped smoking and used EC instead. Accurate nicotine knowledge was not significantly associated with the odds of responding that EC are less addictive than tobacco cigarettes (Table 3).

Perceived main harms of EC

The top five concerns for participants around EC (at least one-third of the sample) were: ‘not enough research has been done to understand all the possible harms’; ‘chemicals in the liquid might be harmful’; ‘not enough quality control or regulation; you don’t know exactly what you are getting’; ‘they may be addictive’; and ‘they may explode or catch fire’ (Table 4).

Perceived main harms differed significantly by vaping status for most items (Table 4). A lower percentage of non-daily vapers endorsed that there had not been enough research to understand all possible harms. There was a lower percentage of daily and non-daily vapers who endorsed that the chemicals in the liquid might be harmful; there is not enough quality control or regulation; EC may explode or catch fire; and EC may reinforce the smoking habit. A higher percentage of triers endorsed that the chemicals in the liquid might be harmful; not enough quality control or regulation; EC may explode or catch fire; and EC may cause breathing or respiratory problems. A higher percentage of never vapers endorsed that there is not enough quality control or regulation; EC may explode or catch fire; EC may reinforce the smoking habit; and EC may cause cancer. There was no significant difference based on vaping status to being concerned about nicotine, that EC may be addictive or that they may cause heart disease.

DISCUSSION

Main findings

The first aim of this study was to investigate nicotine knowledge and perceptions of harm of EC and NRT relative
Table 2 Portion of health risk which comes from nicotine in cigarettes, and the odds of responding that nicotine in cigarettes is not what causes most of the cancer, predicted from demographics using logistic regression; % shows proportion endorsing each of the statements.

| Demographics                | (i) None/very small amount of health harms of tobacco cigarettes comes from nicotine | (ii) Nicotine in cigarettes is not what causes most of the cancer |
|-----------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------|
|                             | Bivariate | Multivariable | Bivariate | Multivariable |
|                             | %         | OR (95% CI)  | P         | OR (95% CI)  | P         | OR (95% CI)          | P         | OR (95% CI)          | P         |
| Gender                      |           |              |           |              |           |                     |           |                     |           |
| Female                      | 9.8       | ref          | ref       |           |           | 59.1               | ref       | 59.1               | ref       |
| Male                        | 12.3      | 1.29 (0.95–1.76) | 0.10     | 1.25 (0.91–1.72) | 0.18     | 62.1               | 1.13 (0.93–1.38) | 0.21     | 1.10 (0.90–1.35) | 0.35     |
| Age (years)                 |           |              |           |              |           |                     |           |                     |           |
| 65+                         | 7.4       | ref          | ref       |           |           | 55.2               | ref       | 55.2               | ref       |
| 55–64                       | 14.3      | 2.10 (1.26–3.52) | 0.005    | 1.93 (1.14–3.27) | 0.014    | 63.1               | 1.39 (1.01–1.90) | 0.041    | 1.31 (0.95–1.80) | 0.10     |
| 45–54                       | 12.8      | 1.84 (1.12–3.03) | 0.016    | 1.57 (0.94–2.62) | 0.082    | 67.3               | 1.67 (1.25–2.25) | 0.001    | 1.53 (1.13–2.06) | 0.006    |
| 35–44                       | 13.4      | 1.95 (1.16–3.28) | 0.012    | 1.73 (1.01–2.96) | 0.046    | 63.3               | 1.40 (1.02–1.92) | 0.036    | 1.27 (0.92–1.76) | 0.14     |
| 25–34                       | 6.9       | 0.93 (0.49–1.76) | 0.82     | 0.87 (0.45–1.67) | 0.67     | 55.1               | 1.00 (0.72–1.38) | 0.98     | 0.94 (0.67–1.32) | 0.72     |
| 18–24                       | 10.6      | 1.49 (0.67–3.32) | 0.33     | 1.27 (0.56–2.90) | 0.57     | 49.4               | 0.79 (0.49–1.28) | 0.34     | 0.71 (0.44–1.16) | 0.17     |
| Smoking status              |           |              |           |              |           |                     |           |                     |           |
| Daily smoker                | 9.4       | ref          | ref       |           |           | 59.7               | ref       | 59.7               | ref       |
| Non-daily                   | 9.9       | 1.05 (0.67–1.67) | 0.82     | 1.07 (0.67–1.72) | 0.77     | 56.9               | 0.89 (0.68–1.17) | 0.41     | 0.92 (0.69–1.23) | 0.58     |
| Ex-smoker                   | 14.6      | 1.65 (1.19–2.28) | 0.003    | 1.41 (0.98–2.03) | 0.06     | 64.2               | 1.21 (0.97–1.51) | 0.086    | 1.18 (0.93–1.49) | 0.18     |
| Vaping status               | < 0.001   | < 0.001      | < 0.001   | < 0.001     | < 0.001   |                     | < 0.001   | < 0.001     | < 0.001     |                     |
| Never vaped                 | 7.2       | ref          | ref       |           |           | 54.9               | ref       | 54.9               | ref       |
| Daily vapor                 | 21.9      | 3.62 (2.43–5.41) | < 0.001  | 3.23 (2.13–4.90) | < 0.001  | 72.2               | 2.13 (1.59–2.86) | < 0.001  | 1.97 (1.46–2.67) | < 0.001  |
| Non-daily vapor             | 6.1       | 0.84 (0.44–1.58) | 0.59     | 0.89 (0.47–1.70) | 0.72     | 53.3               | 0.94 (0.69–1.27) | 0.67     | 0.97 (0.70–1.33) | 0.85     |
| Trier                       | 13.6      | 2.04 (1.31–3.18) | 0.002    | 2.20 (1.39–3.48) | 0.001    | 67.7               | 1.72 (1.29–2.29) | < 0.001  | 1.78 (1.32–2.39) | < 0.001  |
| Ex-vaper                    | 10.4      | 1.51 (0.91–2.90) | 0.11     | 1.41 (0.84–2.37) | 0.19     | 60.8               | 1.27 (0.94–1.72) | 0.11     | 1.25 (0.92–1.70) | 0.16     |
| Income                      |           |              |           |              |           |                     |           |                     |           |
| Low                         | 10.3      | ref          | ref       |           |           | 57.9               | ref       | 57.9               | ref       |
| Moderate                    | 11.5      | 1.13 (0.73–1.74) | 0.59     | 1.11 (0.71–1.73) | 0.66     | 61.3               | 1.15 (0.87–1.51) | 0.32     | 1.16 (0.88–1.54) | 0.29     |
| High                        | 11.5      | 1.13 (0.74–1.70) | 0.58     | 1.00 (0.64–1.54) | 0.99     | 62.6               | 1.22 (0.94–1.58) | 0.14     | 1.16 (0.89–1.53) | 0.28     |
| Not disclosed               | 10.8      | 1.06 (0.58–1.94) | 0.86     | 1.04 (0.56–1.95) | 0.90     | 57.3               | 0.98 (0.67–1.43) | 0.90     | 0.99 (0.67–1.46) | 0.95     |

OR = odds ratio; CI = confidence interval; n = 1720. (i) \( R^2 = 0.039 \) (Cox & Snell), 0.007 (Nagelkerke). Model \( \chi^2_{15} = 67.80, P < 0.001 \). (ii) \( R^2 = 0.035 \) (Cox & Snell), 0.048 (Nagelkerke). Model \( \chi^2_{15} = 61.84, P < 0.001 \). Bold type = \( P < 0.05 \); ref = reference category.
Table 3 Multivariable logistic regressions predicted from demographics and nicotine knowledge for: (i) relative harm perception of EC versus tobacco cigarettes; (ii) relative harm perception of NRT versus tobacco cigarettes; (iii) responding EC are less addictive than tobacco cigarettes; and (iv) perceived change in harm if a smoker stopped smoking and used EC instead; % shows proportion endorsing each of the statements.

| Demographics | (i) EC are less harmful than tobacco cigarettes | (ii) NRT are less harmful than tobacco cigarettes | (iii) EC are less addictive than tobacco cigarettes | (iv) Replacing smoking with EC would reduce health harms a great deal |
|--------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------------------|
| Variable     | % OR (95% CI) P                              | % OR (95% CI) P                               | % OR (95% CI) P                               | % OR (95% CI) P                                              |
| Gender       |                                              |                                              |                                              |                                                              |
| Female       | 55.7 ref (0.84–1.27) 0.78                    | 64.6 ref                                     | 22.7 ref (1.02–1.63) 0.034                    | 32.9 ref (0.69–1.08) 0.19                                    |
| Male         | 58.5 1.03                                   | 62.5 0.83 (0.67–1.02) 0.079                  | 27.6 1.29                                    | 31.6 0.86                                                   |
| Age (years)  |                                              |                                              |                                              |                                                              |
| 65+          | 59.9 ref                                    | 63.4 ref                                     | 25.1                                         | 35.1 0.90                                                   |
| 65–64        | 59.9 0.77 (0.55–1.08) 0.13                    | 66.9 1.01 (0.73–1.42) 0.95                   | 23.6 0.75 (0.52–1.10) 0.14                     | 36.6 0.83                                                   |
| 45–54        | 58.3 0.65 (0.47–0.89) 0.008                    | 67.1 0.99 (0.72–1.35) 0.94                   | 24.6 0.78 (0.55–1.10) 0.16                     | 33.7 0.67                                                   |
| 35–44        | 55.6 0.55 (0.39–0.77) 0.001                    | 62.0 0.75 (0.54–1.05) 0.10                   | 28.1 0.88 (0.60–1.27) 0.48                     | 27.8 0.53                                                   |
| 25–34        | 49.8 0.49 (0.35–0.71) 0.001                    | 53.0 0.58 (0.40–0.82) 0.002                   | 32.9 1.07 (0.62–1.85) 0.81                     | 36.5 0.86                                                   |
| 18–24        | 60.0 0.70 (0.41–1.17) 0.17                    | 68.2 1.12 (0.66–1.91) 0.67                   |                                              |                                                              |
| Smoking status|                                              |                                              |                                              |                                                              |
| Daily smoker |                                              |                                              |                                              |                                                              |
| Non-daily    |                                              |                                              |                                              |                                                              |
| Ex-smoker    |                                              |                                              |                                              |                                                              |
| Vaping status|                                              |                                              |                                              |                                                              |
| Never vaped  |                                              |                                              |                                              |                                                              |
| Daily vaper  |                                              |                                              |                                              |                                                              |
| Non-daily vaper |                                              |                                              |                                              |                                                              |
| Trier        |                                              |                                              |                                              |                                                              |
| Ex-vaper     |                                              |                                              |                                              |                                                              |
| Income       |                                              |                                              |                                              |                                                              |
| Low          |                                              |                                              |                                              |                                                              |
| Moderate     |                                              |                                              |                                              |                                                              |
| High         |                                              |                                              |                                              |                                                              |
| Not disclosed|                                              |                                              |                                              |                                                              |
| Nicotine knowledge |                                        |                                              |                                              |                                                              |
| Health risk from nicotine |                                |                                              |                                              |                                                              |
| Accurate (none or very small) | 77.1 1.82 (1.24–2.66) 0.002 | 82.8 2.29 (1.52–3.44) 0.001 | 29.7 1.11 (0.77–1.59) 0.58 | 55.2 2.15 (1.54–2.99) 0.001 |

(Continues)
to smoking, addictiveness of EC relative to smoking and change in harm to user if smoking was replaced with EC. Relative harm misperceptions of EC, NRT and tobacco cigarettes were common, with only approximately half believing accurately that EC were less harmful and just fewer than two-thirds believing accurately that NRT was less harmful than tobacco smoking. Approximately a quarter perceived EC as less addictive than cigarettes.

The second aim was to see the associations of these perceptions with respondent characteristics, including nicotine knowledge. Perceptions mainly differed by vaping status; those who had never vaped were more likely to have misperceptions about the relative harm of EC and NRT compared with tobacco cigarettes.

There was also some variation based on smoking status, age, gender and income. Knowledge of nicotine was poor: just fewer than nine of 10 smokers and ex-smokers misattributed a greater portion of the risk in smoking to nicotine, and nearly four of 10 wrongly believed that nicotine is what causes cancer from smoking. Both inaccuracies were more common in those who had never vaped and those over 65 years. Inaccurate nicotine knowledge was associated with greater misperceptions of the relative harm of EC, NRT and tobacco cigarettes; however, inaccurate nicotine knowledge was not associated with perceiving EC as less addictive relative to tobacco cigarettes.

The third aim of the study was to explore main concerns around EC. The main perceived concerns around EC were that more research, regulation and quality control were needed on EC and concerns around chemicals in the liquid. These concerns were more likely among those who had never used EC, or only tried them, as opposed to daily and non-daily vapers.

What the results add to the literature

The results provide greater detail on perceptions of relative harm and the correlates of harm perception among a general population sample of UK smokers and ex-smokers. Given that vaping status was associated with harm perceptions, it is possible that those who do not vape may not be using EC due to concerns about potential harms. This is in line with previous findings that fewer concerns about EC harms predicted EC use [9], and also supports previous research which found that users of nicotine products such as EC and NRT are more likely to correctly perceive relative harmfulness [7,9]. Alongside earlier data from the same longitudinal survey [9], which showed a decline in the proportion perceiving EC to be less harmful than cigarettes between 2012 and 2014, the present findings suggest that this trend of increased misperception has continued. It is unclear whether these misperceptions have been impacted by
the revised EU TPD. This paper provides new information about NRT perceptions which, despite being licensed medications and being on the market for decades, are still perceived by more than a third of smokers and ex-smokers as not less harmful than cigarettes.

Findings on inaccurate nicotine knowledge were in line with previous research, such as Siahpush et al. [8], who reported inaccurate understanding around links between nicotine and cancer. The results suggest that nicotine misperceptions may be related to misperceptions concerning the relative harmfulness of EC, NRT and smoking. Correcting misperceptions concerning nicotine may therefore help with understanding about the relative risks of different nicotine delivery products. Addictiveness perceptions of EC versus smoking were not, however, related to inaccurate knowledge. Perceptions have not always been found to be associated with usage [10], as there may be a complex interplay at work between accurate knowledge, harm perceptions and usage. Further research should examine in detail beliefs concerning nicotine and their role in harm perceptions.

Limitations

This study recruited individuals who smoke currently, or used to smoke; it does not include the perspective of the small group of those who vape but have never smoked [4,5]. In addition, participants in this study may differ from the general population of smokers, as those who self-select into research may have different views to those who do not choose to participate in research. Also, the relative harm perception items do not differentiate between harm to the smoker/ex-smoker and others around the individual. Future research should consider the perspective of only-vapers and differentiate harm perceptions to smokers, ex-smokers and never-smokers in future research. In particular, this sample had more older participants and fewer younger ones, so it would be useful to conduct further research looking at the harm perceptions of younger smokers and vapers. In addition, due to attrition, the sample may not be representative; however, as it was a large sample, there was still a good spread across gender, income, smoking and vaping status. Despite adjustment for key

Table 4 Summary of ‘yes’ responses to questions around the perceived main harms of EC.

| Perceived main harms of EC | % 'Yes' response to perceived concerns with EC (n) |  |  |  |  |  | \( \chi^2 \) (d.f.), P |
|---------------------------|-----------------------------------------------|---|---|---|---|---|---|
|                           | Total % yes (n = 1720) | Daily vaper (n = 302) | Non-daily vaper (n = 214) | Vaping trier (n = 294) | Ex-vaper (n = 240) | Never vaper (n = 670) |
| There has not been enough research done to understand all the possible harms | 48.3 (830) | 46.0 (139) | 37.9b (81) | 51.7 (152) | 47.9 (115) | 51.2 (343) | \( \chi^2_{(4)} = 13.61, P = 0.009 \) |
| The chemicals in the liquid might be harmful | 41.6 (715) | 33.4b (101) | 34.1a (73) | 49.3a (145) | 43.8 (105) | 43.4 (291) | \( \chi^2_{(4)} = 21.81, P < 0.001 \) |
| There is not enough quality control or regulation—you don’t know exactly what you are getting | 37.8 (650) | 24.5b (74) | 27.1b (58) | 48.0b (141) | 36.3 (87) | 43.3b (290) | \( \chi^2_{(4)} = 54.85, P < 0.001 \) |
| They may be addictive | 33.3 (572) | 32.1 (97) | 29.4 (63) | 32.3 (95) | 37.5 (90) | 33.9 (227) | \( \chi^2_{(4)} = 3.76, P = 0.44 \) |
| They may explode or catch fire | 36.9 (572) | 24.8b (75) | 21.5b (46) | 41.5b (122) | 34.2 (82) | 33.3a (247) | \( \chi^2_{(4)} = 36.00, P < 0.001 \) |
| They reinforce the smoking habit | 30.2 (520) | 19.9b (60) | 22.9a (49) | 32.7 (96) | 33.3 (80) | 35.1b (235) | \( \chi^2_{(4)} = 30.20, P < 0.001 \) |
| They may cause breathing/respiratory problems | 23.4 (402) | 19.2 (58) | 18.2 (39) | 28.2a (83) | 28.3 (68) | 23.0 (154) | \( \chi^2_{(4)} = 13.32, P = 0.01 \) |
| The nicotine | 22.9 (394) | 24.2 (73) | 22.0 (47) | 22.8 (67) | 24.6 (59) | 22.1 (148) | \( \chi^2_{(4)} = 1.02, P = 0.91 \) |
| They may cause cancer | 14.5 (250) | 10.9 (33) | 10.8 (23) | 14.3 (42) | 14.6 (35) | 17.5a (117) | \( \chi^2_{(4)} = 10.27, P = 0.036 \) |
| They may cause heart disease | 8.8 (152) | 6.6 (20) | 7.5 (16) | 8.8 (26) | 12.1 (29) | 9.1 (61) | \( \chi^2_{(4)} = 5.53, P = 0.24 \) |
| There are no harms | 2.8 (49)a | – | – | – | – | – | – |

Response options ‘yes’ or ‘no’. Bold type = \( P < 0.05 \), "indicates an adjusted standardized residual is greater than 2 and \( \text{b} \) indicates an adjusted standardized residual greater than 3. "This variable had a sample size below 50, so \( \chi^2 \) analyses were not conducted, as there was insufficient cell counts across the vaping categories. EC = electronic cigarettes; d.f. = degrees of freedom.
variables, a potential for unmeasured confounding remains, e.g. one variable which may reasonably be expected to be associated with harm perception is experience of smoking-related illness by the respondent themselves or those close to them.

Implications

It would be useful to explore why these misperceptions exist. This may be influenced by conflicting media reports on the topic and prominent reporting of malfunctioning devices, while fewer headlines are made by the approximately 1500 people who die from smoking-related illness every week in England alone [4]. It might also be that the increasing pressure to regulate e-cigarettes may be contributing to the perception that ‘they are more harmful’.

Furthermore, while many participants had inaccurate perceptions, a substantial number of participants replied they did not know, highlighting the need for more education and awareness. Misperceptions of the relative harms of EC and NRT compared with smoking tobacco cigarettes need to be targeted in public awareness campaigns and policy. In particular, public awareness campaigns should differentiate the role of smoke constituents other than nicotine in causing the main health harms (cancer, heart attacks, stroke) from the role of nicotine in continuing the addiction yet not having the same main health harms. Future research should also explore change mechanisms in harm perceptions to understand how to reverse the shifts in harm perceptions, and move towards more accurate understanding in the community. Accurate understanding is likely to assist smokers in making informed decisions around smoking, EC use and NRT in the aim to reduce health harms related to smoking tobacco cigarettes.

CONCLUSION

The relative harms of EC and NRT compared to smoking tobacco cigarettes and the role of nicotine in the main health harms of smoking were overestimated by large proportions of smokers and ex-smokers. These misperceptions have increased over time, and those who have never vaped are more likely to have misperceptions about relative harmfulness. Inaccurate nicotine knowledge was associated with increased relative harm misperceptions of EC and NRT compared to tobacco cigarettes.

Declaration of interests

None.

Acknowledgements

Cancer Research UK (C52999/A21496; C57277/A23884) funded the work reported in this manuscript. LB’s post is funded by a CRUK/BUPA Foundation Cancer Prevention Fellowship (C52999/A19748). LB and AMcN are part of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collaboration Public Health Research: Centre of Excellence. Funding from the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged (MR/K023195/1). The funders played no role in the study design, collection, analysis and interpretation of the data, in the writing of the manuscript and in the decision to submit this manuscript for publication.

References

1. Drug and Therapeutics Bulletin Republished: nicotine and health. BMJ 2014: 349: 2014.
2. Tobacco Advisory Group of the Royal College of Physicians. Nicotine without smoke—tobacco harm reduction. London: Royal College of Physicians; 2016.
3. Murray R. P., Connett J. E., Zapawa L. M. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. *Nicotine Tob Res* 2009; 11: –1082.
4. McNeill A., Brose L. S., Calder R., Bauld L., Robson D. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. London: Public Health England; 2018, p. 6.
5. McNeill A., Brose L. S., Calder R., Hitchman S. C., Hajek P., McRobbie H. E-cigarettes: An Evidence Update. A report commissioned by Public Health England. London: Public Health England 2015.
6. Shahab L., Goniewicz M. L., Blount B. C., Brown J., McNeill A., Alwis K. U. et al. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. *Ann Intern Med* 2017; 166: 390–400.
7. Czoli C. D., Fong G. T., Mays D., Hammond D. How do consumers perceive differences in risk across nicotine products? A review of relative risk perceptions across smokeless tobacco, e-cigarettes, nicotine replacement therapy and combustible cigarettes. *Tob Control* 2017; 26: e49–e58.
8. Siahpush M., McNeill A., Hammond D., Fong G. T. Socioeconomic and country variations in knowledge of health risks of tobacco smoking and toxic constituents of smoke: results from the 2002 International Tobacco Control (ITC) Four Country Survey. *Tob Control* 2006; 15: iii65–iii70.
9. Brose L. S., Brown J., Hitchman S. C., McNeill A. Perceived relative harm of electronic cigarettes over time and impact on subsequent use. A survey with 1-year and 2-year follow-ups. *Drug Alcohol Depend* 2015; 157: 106–11.
10. Black A., Beard E., Brown J., Fidler J., West R. Beliefs about the harms of long-term use of nicotine replacement therapy: perceptions of smokers in England. *Addiction* 2012; 107: 2037–42.
11. Borland R., Cooper J., McNeill A., O’Connor R., Cummings K. M. Trends in beliefs about the harmfulness and use of stop-smoking medications and smokeless tobacco products among
cigarettes smokers: findings from the ITC four-country survey. Harm Reduct J 2011; 8: 21.

12. Eastwood B., East K., Brose L. S., Dockrell M. J., Arnott D., Cheeseman H., et al. Electronic cigarette use in young people in Great Britain 2015–2016. Public Health 2017; 149: 45–8.

13. Huerta T. R., Walker D. M., Mullen D., Johnson T. J., Ford E. W. Trends in e-cigarette awareness and perceived harmfulness in the U.S. Am J Prev Med 2017; 52: 339–46.

14. Majeed B. A., Weaver S. R., Gregory K. R., Whitney C. F., Slovic P., Pechacek T. F. et al. Changing perceptions of harm of e-cigarettes among U.S. adults, 2012-2015. Am J Prev Med 2017; 52: 331–8.

15. Fidler J. A., Shahab L., West O., Jarvis M. J., McEwen A., Stapleton J. A. et al. ‘The smoking toolkit study’; a national study of smoking and smoking cessation in England. BMC Public Health 2011; 11: 479.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1** Demographic information and recoding of variables (wave 5).